Skip to main content

Research Repository

Advanced Search

Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation

Corsetti, Maura; Landes, Sabine; Lange, Robert

Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation Thumbnail


Authors

MAURA CORSETTI Maura.Corsetti@nottingham.ac.uk
Clinical Associate Professor

Sabine Landes

Robert Lange



Abstract

Background: Bisacodyl is a member of the diphenylmethane family and is considered to be a stimulant laxative. It has a dual prokinetic and secretory action and needs to be converted into the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) in the gut to achieve the desired laxative effect. Bisacodyl acts locally in the large bowel by directly enhancing the motility, reducing transit time and increasing the water content of the stool. A recent network meta-analysis concluded that bisacodyl showed similar efficacy to prucalopride, lubiprostone, linaclotide, tegaserod, velusetrag, elobixibat and sodium picosulfate for the primary endpoint of ≥3 complete spontaneous bowel movements (CSBM)/week and an increase of ≥1 CSBM/week over baseline. The meta-analysis also found that bisacodyl may be superior to the other laxatives for the secondary endpoint of change from baseline in the number of spontaneous bowel movements per week in patients with chronic constipation. This observation stimulated the authors to review the available literature on bisacodyl, which has been available on the market since the 1950s.

Purpose: The aim of the current review was to provide an overview of the historic background, structure, function and mechanism of action of bisacodyl. Additionally, we discuss the important features and studies for bisacodyl to understand its peculiar characteristics and guide its use in clinical practice, but also stimulate research on open questions.

Citation

Corsetti, M., Landes, S., & Lange, R. (2021). Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. Neurogastroenterology and Motility, 33(10), Article e14123. https://doi.org/10.1111/nmo.14123

Journal Article Type Review
Acceptance Date Feb 9, 2021
Online Publication Date Mar 9, 2021
Publication Date 2021-10
Deposit Date Feb 10, 2021
Publicly Available Date Mar 10, 2022
Journal Neurogastroenterology and Motility
Print ISSN 1350-1925
Electronic ISSN 1365-2982
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 33
Issue 10
Article Number e14123
DOI https://doi.org/10.1111/nmo.14123
Keywords Bisacodyl; constipation; laxative; mode of action; secretagogue; sodium picosulfate
Public URL https://nottingham-repository.worktribe.com/output/5315288
Publisher URL https://onlinelibrary.wiley.com/doi/10.1111/nmo.14123

Files





You might also like



Downloadable Citations